<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951076</url>
  </required_header>
  <id_info>
    <org_study_id>BNC210.012</org_study_id>
    <nct_id>NCT04951076</nct_id>
  </id_info>
  <brief_title>A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)</brief_title>
  <acronym>ATTUNE</acronym>
  <official_title>A Phase 2b, Randomized, Double Blind, Two Arm Study to Investigate the Effects of BNC210 Tablet Formulation Compared to Placebo in Adults With Post-Traumatic Stress Disorder (PTSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionomics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionomics Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of BNC210 compared to placebo on PTSD&#xD;
      symptom severity as measured by CAPS-5 Total Symptom Severity Scores.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study&#xD;
      with a 12 week, 2-arm treatment period. Participants will attend a Screening visit within 3&#xD;
      weeks before randomization to confirm eligibility. Approximately 200 participants will be&#xD;
      randomized using a 1:1 ratio to receive either BNC210 900 mg twice daily (b.i.d.) or matched&#xD;
      placebo. Participants will then complete 12 weeks of treatment with their allocated study&#xD;
      intervention. Participants will return to their study site at 4-weekly intervals to receive&#xD;
      study intervention and complete safety and efficacy assessments. Participants are then&#xD;
      requested to attend a Follow-up visit at Week 15 (i.e., 3 weeks after their last study&#xD;
      intervention is administered).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale for DSM-5 (CAPS-5)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from Baseline on Investigator-rated symptoms of PTSD (total symptom severity scores)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician Administered PTSD Scale for DSM-5 (CAPS-5)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from Baseline on Investigator-rated symptom clusters of PTSD (symptom cluster scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Administered PTSD Scale for DSM-5 (CAPS-5)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Response rate and remission rate using Investigator-rated symptoms of PTSD (total symptom severity scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTSD Checklist for DSM-5 (PCL-5)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from Baseline on patient-reported symptoms of PTSD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from Baseline on Investigator-rated symptoms of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from Baseline on Investigator-rated symptoms of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Global Impression (CGI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from Baseline on Investigator-rated global functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression (PGI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from Baseline on patient-reported global functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index (ISI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from Baseline on patient-reported sleep quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale (SDS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from Baseline on patient-reported social functioning</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>BNC210</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BNC210</intervention_name>
    <description>BNC210 900 mg twice daily (b.i.d.) for 12 weeks</description>
    <arm_group_label>BNC210</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice daily (b.i.d.) for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with a current diagnosis of PTSD as defined by the CAPS-5 for DSM-5, with&#xD;
             a CAPS-5 Total Symptom Severity Score of ≥30 at Screening and Baseline and no &gt;25%&#xD;
             decrease in Score from Screening to Baseline&#xD;
&#xD;
          -  The index trauma event must have occurred in adulthood, i.e., when the participant was&#xD;
             ≥18 years of age&#xD;
&#xD;
          -  Suitable contraception use in line with protocol requirements&#xD;
&#xD;
          -  Ability to swallow tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A period of less than 6 months since the index trauma event&#xD;
&#xD;
          -  Current and ongoing exposure to the trauma that caused the PTSD&#xD;
&#xD;
          -  Complex PTSD&#xD;
&#xD;
          -  Severe depression as measured by a score of ≥ 35 on the MADRS&#xD;
&#xD;
          -  Borderline personality disorder, bipolar disorder and other psychotic disorders&#xD;
&#xD;
          -  Use of antidepressant medications within 30 days (fluoxetine within 90 days) of&#xD;
             Screening. The use of alprazolam, flunitrazepam and chronic daily use of other&#xD;
             benzodiazepines within 90 day of Screening.&#xD;
&#xD;
          -  Failed more than three trials of antidepressant medication(s) prescribed for the&#xD;
             treatment of PTSD.&#xD;
&#xD;
          -  Concurrent trauma-based psychotherapy such as Cognitive Behavior Therapy, Prolonged&#xD;
             Exposure Therapy, Eye Movement Desensitization and Reprocessing Therapy. Participants&#xD;
             may however continue to receive supportive counseling that has been in place for a&#xD;
             minimum of three months prior to Screening.&#xD;
&#xD;
          -  Any moderate or severe substance use disorder in the past 12 months&#xD;
&#xD;
          -  Any clinically significant medical history or findings as determined by the&#xD;
             Investigator that could interfere with the objectives of the study or put the&#xD;
             participant at risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BNC210 Clinical Studies Bionomics Limited</last_name>
    <phone>+61 8 8150 7400</phone>
    <email>bnc210clinicalstudies@bionomics.com.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>92591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTTUNE Study Clinical Trial Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>11516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78737</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ATTUNE Study Clinical Trial Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

